Cardamom Extract
Research reviewed: Up until 03/2026
Cardamom Extract (Elettaria cardamomum (Green Cardamom)) is a dietary supplement with 9 published peer-reviewed studies involving 363 participants, researched for Blood Pressure & Antioxidant Effects, Metabolic & Anti-inflammatory Properties.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Blood Pressure & Antioxidant Effects
StrongMetabolic & Anti-inflammatory Properties
StrongResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Blood Pressure & Antioxidant Effects
To evaluate the antihypertensive effects of cardamom supplementation in newly diagnosed essential hypertension patients.
Study Type
Randomised, single-blind, placebo-controlled
Purpose
To evaluate the antihypertensive effects of cardamom supplementation in newly diagnosed essential hypertension patients.
Dose
3 g/day cardamom powder
Participants
20 newly diagnosed stage I hypertensive patients
Duration
12 weeks
Results
Cardamom significantly reduced SBP (from 145 to 129 mmHg) and DBP (from 96 to 84 mmHg) after 12 weeks. Total antioxidant capacity increased by 90%. Fibrinogen was reduced, suggesting anti-thrombotic benefit. The study was the first controlled human trial confirming cardamom's antihypertensive effects.
How They Measured It
Blood pressure, antioxidant status (FRAP, plasma antioxidant capacity), fibrinogen, lipid panel
To investigate green cardamom effects on metabolic syndrome components and cardiovascular risk markers.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To investigate green cardamom effects on metabolic syndrome components and cardiovascular risk markers.
Dose
3 g/day green cardamom capsules
Participants
80 adults with prediabetes and metabolic syndrome criteria
Duration
8 weeks
Results
Cardamom significantly reduced SBP (−8.3 mmHg), fasting glucose, TC, TG, and CRP vs placebo. HDL-C improved slightly. Insulin resistance was reduced. Multiple metabolic syndrome components improved simultaneously, highlighting cardamom's multi-target cardiovascular benefits.
How They Measured It
Blood pressure, glucose, TC, TG, HDL-C, LDL-C, CRP, BMI
To assess the lipid-lowering and anti-inflammatory effects of cardamom supplementation in overweight individuals.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess the lipid-lowering and anti-inflammatory effects of cardamom supplementation in overweight individuals.
Dose
3 g/day cardamom powder
Participants
80 overweight/obese adults
Duration
12 weeks
Results
Cardamom significantly reduced hs-CRP (−24%) and TG (−14%). TC and LDL-C showed trends toward reduction. Blood pressure was significantly lowered. Adiponectin increased, suggesting improved insulin sensitivity and metabolic function.
How They Measured It
TC, LDL-C, HDL-C, TG, hs-CRP, adiponectin, blood pressure
To review the pharmacological basis and clinical evidence for cardamom's cardiovascular effects.
Study Type
Review — cardamom pharmacology and cardiovascular activity
Purpose
To review the pharmacological basis and clinical evidence for cardamom's cardiovascular effects.
Dose
Various
Participants
Multiple studies reviewed
Duration
Various
Results
Cardamom lowers blood pressure via diuretic effects, calcium channel antagonism, and ACE inhibition. Antioxidant activity is attributed to terpenoids (cineole, terpinen-4-ol) and flavonoids. Human trials consistently show 8–15 mmHg SBP reductions and improved antioxidant status with 3 g/day supplementation.
How They Measured It
Narrative review of in vitro, animal, and human data on BP, lipids, and inflammation
Comparison of the effect of ice sucking containing peppermint (Mentha piperita L.) with cardamom (Elettaria cardamomum) extract on nausea, vomiting, and drug request after laparoscopic cholecystectomy
Study Type
Randomised, double-blind, placebo-controlled
Purpose
Comparison of the effect of ice sucking containing peppermint (Mentha piperita L.) with cardamom (Elettaria cardamomum) extract on nausea, vomiting, and drug request after laparoscopic cholecystectomy
Dose
As per study protocol
Participants
See full study
Duration
See full study
Results
Statistically significant findings reported — see full study for complete results.
How They Measured It
See full study for endpoints and measurement methods
Metabolic & Anti-inflammatory Properties
To evaluate cardamom supplementation on hepatic fat and cardiometabolic markers in NAFLD.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate cardamom supplementation on hepatic fat and cardiometabolic markers in NAFLD.
Dose
3 g/day cardamom powder
Participants
68 adults with NAFLD
Duration
3 months
Results
Cardamom significantly reduced hepatic fat (steatosis index improved), liver enzymes (ALT, AST), TC, TG, and CRP. Blood pressure was also reduced vs placebo. Given the cardiovascular risk associated with NAFLD, cardamom's multi-target benefits are clinically meaningful.
How They Measured It
Hepatic steatosis index, liver enzymes, TC, TG, CRP, blood pressure
To study the effect of cardamom on adipokines, inflammatory cytokines, and insulin resistance.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To study the effect of cardamom on adipokines, inflammatory cytokines, and insulin resistance.
Dose
3 g/day green cardamom
Participants
55 adults with type 2 diabetes
Duration
10 weeks
Results
Cardamom significantly increased adiponectin and reduced leptin, TNF-alpha, IL-6, CRP, and HOMA-IR vs placebo. Waist circumference decreased. Anti-inflammatory and insulin-sensitising properties support cardamom's role in reducing cardiometabolic risk.
How They Measured It
Adiponectin, leptin, TNF-alpha, IL-6, CRP, HOMA-IR, waist circumference
To pool the available evidence on cardamom supplementation effects on blood pressure.
Study Type
Meta-analysis
Purpose
To pool the available evidence on cardamom supplementation effects on blood pressure.
Dose
Various (predominantly 3 g/day)
Participants
Multiple RCTs
Duration
8–12 weeks
Results
Pooled analysis confirmed cardamom significantly reduced SBP by −7.4 mmHg and DBP by −4.1 mmHg vs placebo. Effects were more pronounced in hypertensive and metabolic syndrome subjects. Consistent across studies using cardamom powder, extract, or capsule forms.
How They Measured It
Pooled SBP and DBP changes from eligible RCTs
To evaluate the protective effect of cardamom supplementation on endothelial function in patients with ischaemic heart disease.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate the protective effect of cardamom supplementation on endothelial function in patients with ischaemic heart disease.
Dose
3 g/day cardamom powder
Participants
60 patients with stable ischaemic heart disease
Duration
8 weeks
Results
Cardamom significantly improved FMD (+2.4%) and reduced oxidative stress (MDA −22%) and CRP (−18%) compared to placebo. Blood pressure improved. Results provide the first evidence of endothelial protection by cardamom in established cardiovascular disease.
How They Measured It
FMD, brachial blood pressure, oxidative stress markers, CRP
Frequently Asked Questions
Common questions about Cardamom Extract research
There are currently 9 peer-reviewed studies on Cardamom Extract (Elettaria cardamomum (Green Cardamom)), involving 363 total participants. Research covers Blood pressure reduction, Antioxidant support, Metabolic health and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (7 human studies), and reported outcomes.
Cardamom Extract has been researched for: Blood pressure reduction, Antioxidant support, Metabolic health, Anti-inflammatory effects. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 7 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
